Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data

Cybin Inc (NASDAQ:HELP) is among the best psychedelic stocks to buy in 2026. Toronto, Canada-based Cybin Inc. is also known as Helus Pharma. The company has multiple psychedelic drug candidates at various stages, including potential treatments for depression and anxiety disorders.

David Smart/Shutterstock.com

On March 5, Cybin Inc (NASDAQ:HELP) reported topline results from a Phase 2 study of its drug candidate HLP004, which targets patients with generalized anxiety disorder (GAD). That study enrolled three dozen patients who were already on antidepressant therapy but remained symptomatic.

According to the company, HLP004 reduced anxiety symptoms by 10 points on a rating scale. This improvement was above what was already being seen from antidepressant therapy. Moreover, HLP004 was well-tolerated. The benefits of HLP004 were sustained through at least six months, the company said.

Helus Pharma’s other drug candidate, HLP003, is in Phase 3 study for treating major depressive disorder. The company looks to release data on the HLP003 study in Q4 2026.

Cybin Inc (NASDAQ:HELP), also called Helus Pharma, is a Canadian clinical-stage pharmaceutical company focused on developing psychedelic drugs for a variety of mental conditions. It has a large portfolio of drug candidates. Its psilocybin-based drug candidate HLP003, which is in Phase 3 trial, is aimed at a condition known as major depressive disorder (MDD). Its other drug candidate, HLP004, is in Phase 2 trial and targets generalized anxiety disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.